These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 20554786

  • 1. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC.
    Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
    [Abstract] [Full Text] [Related]

  • 2. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 3. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC.
    Endocr Relat Cancer; 2013 Aug 05; 20(4):463-75. PubMed ID: 23653462
    [Abstract] [Full Text] [Related]

  • 4. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Dalino P, Salahuddin N, Korbonits M, Grossman AB.
    Neuroendocrinology; 2008 Aug 05; 87(3):168-81. PubMed ID: 18025810
    [Abstract] [Full Text] [Related]

  • 5. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
    Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC.
    J Clin Endocrinol Metab; 2010 Feb 05; 95(2):968-76. PubMed ID: 19965918
    [Abstract] [Full Text] [Related]

  • 6. mTOR inhibition, a potential novel approach for bronchial carcinoids.
    Dong M, Yao JC.
    Endocr Relat Cancer; 2011 Jun 05; 18(3):C15-8. PubMed ID: 21427170
    [Abstract] [Full Text] [Related]

  • 7. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB.
    Endocr Relat Cancer; 2009 Dec 05; 16(4):1329-38. PubMed ID: 19620247
    [Abstract] [Full Text] [Related]

  • 8. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC.
    Endocr Relat Cancer; 2007 Mar 05; 14(1):91-102. PubMed ID: 17395978
    [Abstract] [Full Text] [Related]

  • 9. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 05; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 10. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 11. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.
    Cancer; 2011 Sep 15; 117(18):4141-54. PubMed ID: 21387274
    [Abstract] [Full Text] [Related]

  • 12. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan 15; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 13. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C.
    Nephrol Dial Transplant; 2006 Oct 15; 21(10):2724-35. PubMed ID: 16861242
    [Abstract] [Full Text] [Related]

  • 14. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K, Rüden Jv, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ.
    Cancer Lett; 2010 Sep 01; 295(1):100-9. PubMed ID: 20356670
    [Abstract] [Full Text] [Related]

  • 15. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, Groh N, Polier A, Brandt I, Lotz L, Hoffmann I, Koppitz F, Oeser S, Mueller A, Fasching PA, Lux MP, Beckmann MW, Schrauder MG.
    Biochem Pharmacol; 2012 Feb 15; 83(4):480-8. PubMed ID: 22142888
    [Abstract] [Full Text] [Related]

  • 16. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 17. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ.
    Neuroendocrinology; 2007 Jan 22; 85(1):54-60. PubMed ID: 17310129
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
    Rico C, Laguë MN, Lefèvre P, Tsoi M, Dodelet-Devillers A, Kumar V, Lapointe E, Paquet M, Nadeau MÈ, Boerboom D.
    Carcinogenesis; 2012 Nov 22; 33(11):2283-92. PubMed ID: 22871496
    [Abstract] [Full Text] [Related]

  • 19. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JM.
    Breast Cancer Res Treat; 2010 Jul 22; 122(2):419-28. PubMed ID: 20480226
    [Abstract] [Full Text] [Related]

  • 20. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O, Inoue T.
    Prostate; 2010 Jun 01; 70(8):866-74. PubMed ID: 20127734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.